AVITA Medical (AVITA Medical) Debt-to-EBITDA : -1.85 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is AVITA Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

AVITA Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.90 Mil. AVITA Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $41.51 Mil. AVITA Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was $-22.98 Mil. AVITA Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for AVITA Medical's Debt-to-EBITDA or its related term are showing as below:

AVHHL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.26 Med: -0.04 Max: -0.01
Current: -1.26

During the past 13 years, the highest Debt-to-EBITDA Ratio of AVITA Medical was -0.01. The lowest was -1.26. And the median was -0.04.

AVHHL's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs AVHHL: -1.26

AVITA Medical Debt-to-EBITDA Historical Data

The historical data trend for AVITA Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical Debt-to-EBITDA Chart

AVITA Medical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Dec22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.05

-0.03

-0.04

-1.26

AVITA Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-0.04	-0.05	-0.04	-0.08	-1.85

Competitive Comparison of AVITA Medical's Debt-to-EBITDA

For the Medical Devices subindustry, AVITA Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVITA Medical's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where AVITA Medical's Debt-to-EBITDA falls into.

AVITA Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

AVITA Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.895	+	41.514)	/	-33.54
	=	-1.26

AVITA Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.895	+	41.514)	/	-22.976
	=	-1.85

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

AVITA Medical (OTCPK:AVHHL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

AVITA Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical (AVITA Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (OTCPK:AVHHL) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

RCEL:USA 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.